Clinical Trial Update: A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL） [Phase 2]

View source ↗

Summary

Phase 2 trial update for TQ-B3525 in relapsed/refractory peripheral T-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• TQ-B3525

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Peripheral T-cell Lymphoma | Phase 2 | Status: UNKNOWN